# Rapid diagnostic solutions for Antimicrobial Resistance

Prof Hywel Morgan Electronics and Computer Science, and Institute for Life Sciences University of Southampton

> Dr Mark Sutton Public Health England

> > Southampto



# UK Government report into Anti-Microbial Resistance (O'Neill), 2016

### **SUMMARY OF RECOMMENDATIONS**

5. Promote new, rapid diagnosis

"...support the use of rapid point-of-care diagnosis... to facilitate the mandatory use of tests to support clinical decision making by 2020



## Public enemies (WHO 2017)

- Priority 1: CRITICAL
- Acinetobacter baumannii, carbapenemresistant
- Pseudomonas aeruginosa, carbapenemresistant
- Enterobacteriaceae, carbapenem-resistant, ESBL-producing
- Priority 2: HIGH
- Enterococcus faecium, vancomycin-resistant
- *Staphylococcus aureus*, methicillin-resistant, vancomycin-intermediate and resistant
- *Helicobacter pylori,* clarithromycin-resistant
- *Campylobacter* spp., fluoroquinolone-resistant
- Salmonellae, fluoroquinolone-resistant

#### cont..

- Neisseria gonorrhoeae, cephalosporinresistant, fluoroquinolone-resistant
- **Priority 3: MEDIUM**
- Streptococcus pneumoniae, penicillin-nonsusceptible

Haemophilus influenzae, ampicillin-resistant

Shigella spp., fluoroquinolone-resistant

# Genotypic vs Phenotypic assay

#### Genotypic (DNA):

#### Pros:

- Very sensitive (1 copy) and rapid (<30 mins)</li>
- Specific for particular gene targets in particular bacteria

#### Cons:

- Does the gene mean that bacteria are viable?
- Can miss gene variants (rapid mutations)
- Need separate assays to detect resistance

Phenotypic (Behaviour):


#### Pros:

- Measures resistance (enzymes) in viable bacteria.
- Could assess susceptibility to antibiotics


#### Cons:

- Low sensitivity requires culture to amplify (6-8 hours)
- False negatives samples which do not grow.
- Persister/viable but nonculturable cells not detected

# Sample preparation – major issue Example: Sepsis



# **Genotypic**: Isothermal DNA amplification



PCR uses temperature cycling to amplify DNA


**Isothermal methods** use alternative methods to unwind DNA for amplification

Single temperature; much easier to implement

тіп ≻ Rapid

- Less affected by PCR inhibitors
- Readout with hybridisation fluorescent probe – minimises false positives
- Chemistry v. stable at R.T.

# Detection of ESBL/carbapenemase genes on a microfluidic system.




• Triplex assay:

KPC; NDM-1; CTX-M-15 (most prevalent in UK)

- **Simple**: Fluorescence measured with LED/Camera
- **Fast**: 15 mins
- Sensitive: LoD of 10 copies
- **Stable**: Assay chemistry stable for weeks at R.T.

### Sample prep (Urinary Tract Infection)



Hole in glass

#### ACCESS

#### Global prevalence of antibiotic resistance in paediatric urinary tract infections caused by *Escherichia coli* and association with routine use of antibiotics in primary care: systematic review and meta-analysis

Ashley Bryce,<sup>1</sup> Alastair D Hay,<sup>1</sup> Isabel F Lane,<sup>1</sup> Hannah V Thornton,<sup>1</sup> Mandy Wootton,<sup>2</sup> Céire Costelloe<sup>3</sup>

#### Primary r Primary ol of Social icine, Bristol BS8

bial Public iology spital of XW, UK ion lthcare s and nce, don, {

A Bryce

#### ABSTRACT

#### **OBJECTIVES**


To systematically review studies investigating the prevalence of antibiotic resistance in urinary tract infections caused by *Escherichia coli* in children and, when appropriate, to meta-analyse the relation between previous antibiotics prescribed in primary care and resistance.


#### DESIGN AND DATA ANALYSIS

Systematic review and meta-analysis. Pooled percentage prevalence of resistance to the most commonly used antibiotics in children in primary care, stratified by the OECD (Organisation for Economic Co-operation and Development) status of the study country. Random effects meta-analysis was used to (95% confidence interval 46.0% to 60.8%) for ampicillin, 23.6% (13.9% to 32.3%) for trimethoprim, 8.2% (7.9% to 9.6%) for co-amoxiclav, and 2.1% (0.8 to 4.4%) for ciprofloxacin; nitrofurantoin was the lowest at 1.3% (0.8% to 1.7%). Resistance in studies in countries outside the OECD was significantly higher: 79.8% (73.0% to 87.7%) for ampicillin, 60.3% (40.9% to 79.0%) for co-amoxiclav, 26.8% (11.1% to 43.0%) for ciprofloxacin, and 17.0% (9.8% to 24.2%) for nitrofurantoin. There was evidence that bacterial isolates from the urinary tract from individual children who had received previous prescriptions for antibiotics in primary care were more likely to be resistant to antibiotics, and this increased risk could persist for up to six months (odds ratio 13.23, 95% confidence interval 7.84 to 22.31).

## Phenotypic: Optical

Q: Does the bacteria carry the enzyme?







Colour change (red to yellow)


**Beta-lactamase** 


## Extended spectrum beta-lactamase (ESBL)













Extract proteins from *E. coli*, mix with nitrocefin, and inject into optical chip.

1.8




# Multi-channel plastic optical absorption chip



Absorbance change of Nitrocefin for *E. coli* with *bla* <sub>CTX-M</sub>

# **Susceptibility** Does the antibiotic kill the bacteria?



Simple chip < \$1

## Challenges:

- Fast, simple assays needed for MIC and organism I.D.
- Improved sample preparation for isolation of bacteria from clinical matrices, blood, urine (eliminate need to culture);
  - 1-3 cfu/ml blood. Needs to cover wide range of pathogens causing sepsis
- Rare cell isolation and analysis
  - e.g. persistor / tolerant cells possibly driving resistance
- Improve biomarker discovery and validation for infectious disease - different cell types and/or exosomes (hose response).

# Acknowledgements

# Southampton

- Dan Spencer
- Sumit Kalsi
- Yuetao Li





Public Health England

Mark Sutton Carrie Turner Collette Allen Dave Jamieson

Technology Strategy Board Driving Innovation



**Olaf Pipenburg** 

**Niall Armes** 

SHARP.




Engineering and Physical Sciences Research Council



The research was funded by the NIHR Invention for Innovation (i4i) programme (project II-ES-0511-21002). The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health

*Funded by* **NHS** National Institute for Health Research

#### **Conductivity Sensor**



1.8 *E. coli* with and without TEM (u) (u) and (u) an


Glucose metabolism in *E. coli*.

Bacteria metabolise glucose into lactate or carbonate, increasing conductivity of the solution.

"*E. coli* student portal - Fermentation", *Ecolistudentportal.org*, 2018. [Online]. Available: http://ecolistudentportal.org/article\_fermentation. [Accessed: 27- Feb- 2018].

### **A PERFECT STORM**

As bacterial infections grow more resistant to antibiotics, companies are pulling out of antibiotics research and fewer new antibiotics are being approved.



\*Proportion of clinical isolates that are resistant to antibiotic. MRSA, methicillin-resistant Staphylococcus aureus. VRE, vancomycin-resistant Enterococcus. FQRP, fluoroquinolone-resistant Pseudomonas aeruginosa.

Fix the antibiotics pipeline Matthew A. Cooper<sup>1</sup> David Shlaes<sup>2</sup> Nature 472, p32 (2011)

## CDC list 2013 and "ESKAPEE" pathogens

1

#### **Public enemies**

Top 15 drug-resistant threats\*, 2013

Threat	Selected effects
URGENT	
Clostridium difficile	diarrhoea, colitis
Carbapenem-resistant Enterobacteriaceae	multiple enteric problems
Neisseria gonorrhoeae	gonorrhoea
SERIOUS	
Multidrug-resistant Acinetobacter	hospital-acquired pneumonia
Drug-resistant Campylobacter	diarrhoea, dysentery
Fluconazole-resistant Candida *	oral and vaginal thrush
Extended-spectrum Enterobacteriaceae	multiple enteric problems
Vancomycin-resistant Enterococcus	urinary tract infection, meningitis
Multidrug-resistant Pseudomonas aeruginosa	sepsis
Drug-resistant non-typhoidal Salmonella	food poisoning
Drug-resistant Salmonella serotype Typhi	typhoid fever
Drug-resistant Shigella	dysentery
Methicillin-resistant Staphylococcus aureus (MRSA)	bacteremia (blood poisoning), sepsis
Drug-resistant Streptococcus pneumoniae	bacteremia, meningitis, pneumonia, sepsis
Drug-resistant Mycobacterium tuberculosis (MDR & XDR)	tuberculosis
CONCERNING	
Vancomycin-resistant Staphylococcus aureus	bacteremia, sepsis
Erythromycin-resistant Group A Streptococcus	bacteremia, pneumonia, sepsis
Clindamycin-resistant Group B Streptococcus	neonatal infections

Sources: CDC; The Economist conomist.com

#### "ESKAPEE" pathogens

Enterococcus faecalis Staphylococcus aureus Klebsiella pneumoniae Acinetobacter baumannii Pseudomonas aeruginosa Enterobacter spp Escherichia coli

And pathogens with intrinsic resistance to antimicrobials *Stenotrophomonas*, *Proteus, Burkholderia*,

\*All bacterial except Candida, which is a fungus

#### "The perfect new rapid diagnostic test would answer four questions" - AMR Review




# The AMR problem

• "Antimicrobial resistance poses a catastrophic threat. If we don't act now, any one of us could go into hospital in 20 years for minor surgery and die because of an ordinary infection that can't be treated by antibiotics"

> – Professor Dame Sally Davies. Chief Medical Officer, England. March 2013

# Ultra-rapid detection of resistance genes using semiconductors






Ultra-fast electronic detection of antimicrobial resistance genes using isothermal amplification and Thin Film Transistor sensors

Chunxiao Hu<sup>a</sup>, Sumit Kalsi<sup>a</sup>, Ioannis Zeimpekis<sup>a</sup>, Kai Sun<sup>a</sup>, Peter Ashburn<sup>a</sup>, Carrie Turner<sup>b</sup>, J. Mark Sutton<sup>b</sup>, Hywel Morgan<sup>a,\*</sup>

#### 10 copies in 5 mins



## WHO antibiotic resistance quiz

http://www.who.int/campaigns/world-antibiotic-awareness-week/quiz/en/

- Quiz: How much do you know about antibiotic resistance?
- 1 Antibiotics are powerful medicines that help to fight:
- Viruses Bacteria All microbes
- 2 Antibiotic resistance happens when my body becomes resistant to antibiotics.
- True False
- 3 Antibiotic-resistant bacteria can spread to humans through:
- Contact with a person who has an antibiotic-resistant infection
- Contact with something that has been touched by a person who has an antibiotic-resistant infection (e.g. a health-workers' hands or instruments in a health facility with poor hygiene)
- Contact with a live animal, food or water carrying antibiotic-resistant bacteria.
- All of the above
- 4 What can happen if I get an antibiotic-resistant infection?
- I may be sick for longer
- I may have to visit my doctor more or be treated in hospital
- I may need more expensive medicine that may cause side effects
- All of the above
- 5 Antibiotic resistance is already out of control and it's only getting worse. There's nothing I can do.
- True
- False
- 6 I can help tackle antibiotic resistance if I:
- Share my antibiotics with my family when they are sick
- Get antibiotics as soon as I feel sick either directly from the pharmacy or a friend
- Keep my vaccinations up to date

### WHO antibiotic resistance quiz

http://www.who.int/campaigns/world-antibiotic-awareness-week/quiz/en/

- Quiz: How much do you know about antibiotic resistance?
- 4 What can happen if I get an antibiotic-resistant infection?
- I may be sick for longer. I may have to visit my doctor more or be treated in hospital
- I may need more expensive medicine that may cause side effects. All of the above
- 5 Antibiotic resistance is already out of control and it's only getting worse. There's nothing I can do.
- True False
- 6 I can help tackle antibiotic resistance if I:
- Share my antibiotics with my family when they are sick.
- Get antibiotics as soon as I feel sick either directly from the pharmacy or a friend.
- Keep my vaccinations up to date